Osteopore Ltd
Research Osteopore Ltd (OSX) on Bullrun: market cap AUD 3.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOSX
- ExchangeAU
- CountrySingapore
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyAUD
- Market capAUD 3.12M
- Financial periodFY2025
- RevenueAUD 3.06M
- Revenue growth5.0%
- Net income-AUD 3.72M
- Free cash flow-AUD 2.55M
- Gross margin77.5%
Valuation Snapshot
latest market cap is AUD 3.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 3.06M | -AUD 3.72M | -AUD 2.55M | 77.5% | n/a | AUD 656.67K | AUD 2.79M | -AUD 1.73M |
| FY2024 | AUD 2.91M | -AUD 3.35M | -AUD 3.10M | 84.0% | -0.03 | AUD 682.26K | AUD 1.33M | AUD 306.22K |
| FY2023 | AUD 2.22M | -AUD 4.87M | -AUD 3.74M | 73.8% | -0.08 | AUD 1.16M | AUD 1.19M | AUD 432.60K |
| FY2022 | AUD 1.69M | -AUD 4.20M | -AUD 4.00M | 75.2% | -0.09 | AUD 2.16M | AUD 74.18K | AUD 2.11M |
| FY2021 | n/a | n/a | n/a | n/a | -0.08 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 3.12M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Osteopore Ltd
Osteopore Limited, a regenerative medicine company, engages in the production of 3D-printed biomimetic and bioresorbable implants in Vietnam, South Korea, the Philippines, Singapore, India, Taiwan, Indonesia, the Netherlands, the United Arab Emirates, Australia, and internationally. The company commercializes products designed to enable natural bone healing across multiple therapeutic areas.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Osteopore Ltd's market cap?
Osteopore Ltd's market capitalization is AUD 3.12M.
What does Osteopore Ltd do?
Osteopore Limited, a regenerative medicine company, engages in the production of 3D-printed biomimetic and bioresorbable implants in Vietnam, South Korea, the Philippines, Singapore, India, Taiwan, Indonesia, the Netherlands, the United Arab Emirates, Australia, and internationally. The company commercializes products designed to enable natural bone healing across multiple therapeutic areas. Its technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.